Merck and Galapagos NV have agreed to end their development alliances, and Galapagos has regained worldwide rights for all assets in the programs. Merck will make a payment of $16.5 million to Galapagos for work completed in 2010. Galapagos has received a total of $28.7 million in upfront and milestone payments from the alliance and has regained worldwide rights to the targets discovered and assays developed from the collaboration. “Changes in our early discovery strategy have required us to ...